Comparative Pharmacology
Head-to-head clinical analysis: CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER versus KEFLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER versus KEFLEX.
CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER vs KEFLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3 in Gram-negative bacteria, leading to cell lysis and death.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
1-2 g IV every 8-12 hours for moderate to severe infections; for febrile neutropenia, 2 g IV every 8 hours.
250-500 mg orally every 6 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life ≈2.0–2.3 hours in healthy adults; prolonged to 13–26 hours in severe renal impairment (CrCl <10 mL/min); relevant for dosing interval adjustment.
0.5–1.2 hours in patients with normal renal function (CrCl >50 mL/min); prolonged to >20 hours in ESRD.
Primarily renal (≈85% unchanged via glomerular filtration and tubular secretion); minimal biliary/fecal (<5%).
Primarily renal (90% or more unchanged via glomerular filtration and tubular secretion); small amounts biliary/fecal (<5%).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic